^
    2d
    Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P3, N=94, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Imbruvica (ibrutinib) • cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate)
    2d
    OASIS-II: Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=194, Active, not recruiting, The Lymphoma Academic Research Organisation | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib)
    3d
    A041702: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P3, N=465, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Dec 2026
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    clonoSEQ
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)
    7d
    CACIS: Cardiovascular Complications of Ibrutinib Therapy (clinicaltrials.gov)
    P=N/A, N=8, Terminated, Centre Hospitalier Universitaire Dijon | N=100 --> 8 | Trial completion date: Mar 2027 --> Aug 2025 | Recruiting --> Terminated | Trial primary completion date: Mar 2027 --> Aug 2025; premature shutdown due to change in processing line
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Imbruvica (ibrutinib)
    7d
    The Care and Cure of the Leukemias in 2026. (PubMed, Am J Hematol)
    Currently, most leukemias are effectively treated with immunotherapies (highly effective monoclonal antibodies targeting CD19 [blinatumomab], or CD22 [inotuzumab ozogamicin]), BCR::ABL1 tyrosine kinase inhibitors (TKIs; e.g., dasatinib, ponatinib), Bruton TKIs (e.g., ibrutinib, acalabrutinib), BCL-2 inhibitors (venetoclax), IDH1/2 inhibitors (ivosidenib, olutasidenib, and enasidenib), FLT3 inhibitors (e.g., midostaurin, quizartinib, and gilteritinib), menin inhibitors (revumenib, ziftomenib), and chimeric antigen receptor T-cell therapies. Herein, we provide a high-level overview of prominent clinical developments across all leukemias. In contemporary times, harnessing the benefits of novel targeted therapies and the evolving treatment landscape bolster the optimistic view that most, if not all, leukemias are curable.
    Review • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • KMT2A (Lysine Methyltransferase 2A) • CD22 (CD22 Molecule)
    |
    TP53 mutation • KMT2A mutation • MLL mutation
    |
    Venclexta (venetoclax) • dasatinib • Imbruvica (ibrutinib) • Iclusig (ponatinib) • Xospata (gilteritinib) • Blincyto (blinatumomab) • midostaurin • Calquence (acalabrutinib) • Vanflyta (quizartinib) • Tibsovo (ivosidenib) • Besponsa (inotuzumab ozogamicin) • Revuforj (revumenib) • Idhifa (enasidenib) • Komzifti (ziftomenib) • Rezlidhia (olutasidenib)
    12d
    Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL. (PubMed, Front Immunol)
    To this end, bridging therapy with Brutonyg tyrosine kinase inhibitors (BTKi), such as ibrutinib or zanubrutinib, is being investigated as a strategy to improve treatment outcomes. Further investigations are essential to validate and translate these observations into clinical practice, thus highlighting the need for further research in this area. https://www.chictr.org.cn/showproj.aspx?proj=33185, ChiCTR1800019622.
    Clinical • Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • NAMPT (Nicotinamide Phosphoribosyltransferase)
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib)
    14d
    Pembrolizumab, Ibrutinib and Rituximab in PCNSL (clinicaltrials.gov)
    P1/2, N=37, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Imbruvica (ibrutinib) • Rituxan (rituximab) • Truxima (rituximab-abbs)
    17d
    Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia (clinicaltrials.gov)
    P2, N=21, Terminated, Mayo Clinic | Trial completion date: Jun 2025 --> Jan 2026
    Trial completion date
    |
    Imbruvica (ibrutinib) • Ninlaro (ixazomib)
    17d
    OSU-16077: Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Feb 2026 --> Aug 2026 | Trial primary completion date: Jan 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Imbruvica (ibrutinib)
    18d
    Real-World Selection of Venetoclax-Obinutuzumab Versus BTK Inhibitor Therapy for Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. (PubMed, Eur J Haematol)
    Time-limited and continuous targeted therapies are used with similar frequency for CLL/SLL, with selection shaped by age, TP53 aberrations, geography, and patient preferences. These findings highlight the importance of personalized care and the need to reduce access barriers to time-limited strategies.
    Journal • Real-world evidence
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 mutation + Chr del(17p)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)
    21d
    A Long-term Extension Study of PCI-32765 (Ibrutinib) (clinicaltrials.gov)
    P3, N=700, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jan 2027 --> Aug 2027
    Trial completion date
    |
    Imbruvica (ibrutinib)
    22d
    Ibrutinib with venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia: A phase II study. (PubMed, Blood Cancer Discov)
    Grade ≥3 neutropenia and thrombocytopenia occurred in 38% and 13% of patients, respectively. The 24-cycle ibrutinib + venetoclax combination led to high rates of CR/CRi and bone marrow U-MRD4 in patients with R/R CLL.
    P2 data • Journal
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
    |
    TP53 mutation • TP53 mutation + Chr del(17p)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib)